BIOGRAPHY

Dr. Michael Yamin is a Scientific Advisor in the Life Sciences Group in Pearl Cohen’s New York office. Michael works primarily in patent drafting, worldwide patent prosecution, patent strategy planning, and portfolio management in the life sciences and biotechnology areas. His technical experience includes pharmaceuticals, formulations, small molecules, molecular biology, immunology, biochemistry, pharmacology, and cellular and developmental biology.

Prior to joining Pearl Cohen, Michael worked at various companies in the New York City area, including Angion Biomedica Corp., Warren Pharmaceuticals, Inc., Mojave Therapeutics, Inc., The Picower Institute for Medical Research, Innapharma, Inc., and Alteon Inc. He was also a research associate at The Rockefeller University. Michael is also a member of the board of directors of Angion Biomedica Corp.


4. Schmidt RE, Feng D, Wang Q, Green KG, Snipes LL, Michael Yamin, Brines M. Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy
